DE602004031435D1 - Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus - Google Patents

Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus

Info

Publication number
DE602004031435D1
DE602004031435D1 DE602004031435T DE602004031435T DE602004031435D1 DE 602004031435 D1 DE602004031435 D1 DE 602004031435D1 DE 602004031435 T DE602004031435 T DE 602004031435T DE 602004031435 T DE602004031435 T DE 602004031435T DE 602004031435 D1 DE602004031435 D1 DE 602004031435D1
Authority
DE
Germany
Prior art keywords
hepatitis
virus
treatment
heterocycles
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004031435T
Other languages
German (de)
English (en)
Inventor
Peter W Glunz
Brent D Douty
Scott W Martin
Jeffrey Romine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of DE602004031435D1 publication Critical patent/DE602004031435D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602004031435T 2003-09-11 2004-08-24 Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus Expired - Lifetime DE602004031435D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50206703P 2003-09-11 2003-09-11
PCT/US2004/027533 WO2005034850A2 (en) 2003-09-11 2004-08-24 Cycloalkyl heterocycles for treating hepatitis c virus

Publications (1)

Publication Number Publication Date
DE602004031435D1 true DE602004031435D1 (de) 2011-03-31

Family

ID=34434839

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004031435T Expired - Lifetime DE602004031435D1 (de) 2003-09-11 2004-08-24 Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus

Country Status (7)

Country Link
US (1) US7112601B2 (cg-RX-API-DMAC10.html)
EP (1) EP1663105B1 (cg-RX-API-DMAC10.html)
JP (1) JP4897484B2 (cg-RX-API-DMAC10.html)
AT (1) ATE498398T1 (cg-RX-API-DMAC10.html)
DE (1) DE602004031435D1 (cg-RX-API-DMAC10.html)
ES (1) ES2358904T3 (cg-RX-API-DMAC10.html)
WO (1) WO2005034850A2 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT502258B1 (de) * 2005-07-22 2007-09-15 Univ Wien Cox-i-inhibitorverbindungen
US20070032488A1 (en) * 2005-08-05 2007-02-08 Genelabs Technologies, Inc. 6-Membered aryl and heteroaryl derivatives for treating viruses
WO2008019477A1 (en) * 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2008106166A2 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
MX2009011930A (es) 2007-05-04 2009-11-18 Vertex Pharma Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.
EP2193807A4 (en) 2007-08-24 2012-09-12 Univ Sapporo Medical CYCLOSPORIN A-BINDING PROTEIN
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
KR20110116136A (ko) 2009-01-07 2011-10-25 싸이넥시스, 인크. Hcv 및 hiv 감염의 치료에 사용하기 위한 사이클로스포린 유도체
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 c형 간염 세린 프로테아제 억제제
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2019169193A1 (en) 2018-03-01 2019-09-06 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9611047A (pt) * 1995-10-17 2000-03-08 Searle & Co Processo de deteção de ciclo oxigenase-2
CA2338490A1 (en) 1998-07-27 2000-02-10 Sergio Altamura Diketoacid-derivatives as inhibitors of polymerases
IL141456A0 (en) 1998-08-21 2002-03-10 Viropharma Inc Rhodanine derivatives and pharmaceutical compositions containing the same
WO2000013708A1 (en) 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
BR9913935A (pt) 1998-09-25 2001-06-19 Viropharma Inc Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
AU1324300A (en) * 1998-10-26 2000-05-15 Vertex Pharmaceuticals Incorporated Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
CZ20013424A3 (cs) 1999-12-27 2002-02-13 Japan Tobacco Inc. Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
EP2363396A1 (en) 2001-06-11 2011-09-07 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
AR035543A1 (es) * 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US20030134853A1 (en) * 2001-09-26 2003-07-17 Priestley Eldon Scott Compounds useful for treating hepatitis C virus

Also Published As

Publication number Publication date
US7112601B2 (en) 2006-09-26
ATE498398T1 (de) 2011-03-15
JP4897484B2 (ja) 2012-03-14
WO2005034850A2 (en) 2005-04-21
ES2358904T3 (es) 2011-05-16
WO2005034850A3 (en) 2006-03-16
US20050075376A1 (en) 2005-04-07
EP1663105B1 (en) 2011-02-16
EP1663105A4 (en) 2009-04-15
EP1663105A2 (en) 2006-06-07
JP2007505114A (ja) 2007-03-08

Similar Documents

Publication Publication Date Title
EA200700338A1 (ru) Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с и композиции и способы лечения с их использованием
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
PL1987038T3 (pl) Inhibitory HCV NS5B
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
CO5630024A2 (es) Compuestos inhibidores de la hepatitis c
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
WO2004002940A8 (en) Inhibitors of hcv ns5b polymerase
EA200900298A1 (ru) Ингибиторы вируса гепатита с
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
EA200800371A1 (ru) Ингибиторы ns3 протеазы вгс
MY164469A (en) Hcv ns3 protease inhibitors
JO2318B1 (en) Nucleoside derivatives used as DNA-based viral RNA inhibitors
ATE498398T1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
MX2012008443A (es) Nucleosidos antiviricos.
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
ATE432922T1 (de) Substituierte 5-carboxyamidpyrazoles und ä1,2, 4ütriazole als viruzide
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
NO20062146L (no) Nukleosidforbindelser for behandling av virusinfeksjoner
UA90909C2 (en) Hcv ns3 protease inhibitors
ATE491706T1 (de) Heterocyclische antivirale verbindungen